Tumors with specific genetic mutations show response to immune checkpoint blockade therapy

New research from a collaborative team at Cleveland Clinic, led by Timothy Chan, MD, Ph.D., Chair of the Center for Immunotherapy and Precision Immuno-Oncology in the Lerner Research Institute, is demonstrating that pathogenic Polymerase epsilon and delta (POLE/POLD1) genetic mutations lead to improved response to immune checkpoint blockade (ICB), a growing class of immunotherapy drugs.

source https://medicalxpress.com/news/2022-07-tumors-specific-genetic-mutations-response.html